INDV:NSD-Indivior PLC Ordinary Shares (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 17.58

Change

+0.33 (+1.91)%

Market Cap

USD 2.93B

Volume

0.18M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
NBIX Neurocrine Biosciences Inc

+0.64 (+0.46%)

USD 13.68B
VTRS Viatris Inc

-0.59 (-5.00%)

USD 13.36B
ITCI Intracellular Th

-1.44 (-2.15%)

USD 7.72B
LNTH Lantheus Holdings Inc

+1.39 (+1.87%)

USD 4.49B
ALKS Alkermes Plc

+0.16 (+0.66%)

USD 4.11B
ALVO Alvotech

+0.06 (+0.44%)

USD 3.79B
HCM HUTCHMED DRC

+1.35 (+6.93%)

USD 3.23B
AVDL Avadel Pharmaceuticals PLC

-0.42 (-2.58%)

USD 2.99B
EVO Evotec SE ADR

+0.08 (+1.54%)

USD 2.51B
AMPH Amphastar P

+0.22 (+0.52%)

USD 2.06B

ETFs Containing INDV

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 15.13% 75% C 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.13% 75% C 81% B-
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 2.93B 92% A 84% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector